Last $3.06 USD
Change Today +0.05 / 1.66%
Volume 1.2M
GERN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

geron corp (GERN) Key Developments

Geron Corporation - Shareholder/Analyst Call

To present a company overview and discuss data presented at the 56th American Society of Hematology (ASH) Annual Meeting; and to discuss preclinical proof-of-concept data on imetelstat in acute myelogenous leukemia which was published in Cell Stem Cell as well as presented at the 56th ASH Annual Meeting

Geron Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 04:00 PM

Geron Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 04:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: John A. Scarlett, Chief Executive Officer, President and Director.

Geron Corporation Enters into License Agreement with Janssen Biotech to Develop Cancer Drug

Geron Corporation has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech Inc. to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Under the terms of the agreement, Geron will receive an initial payment of $35 million due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities.

Geron Corporation, Janssen Biotech, Inc. - Special Call

Geron Corporation, Janssen Biotech, Inc. - Special Call

Geron Corporation Presents at Stifel Healthcare Conference 2014, Nov-19-2014 01:50 PM

Geron Corporation Presents at Stifel Healthcare Conference 2014, Nov-19-2014 01:50 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: John A. Scarlett, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $3.06 USD +0.05

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.49 USD 0.00
BioTime Inc $3.62 USD +0.11
IntelliCell BioSciences Inc $0.0002 USD 0.00
Neuralstem Inc $2.70 USD +0.07
ReNeuron Group PLC 3.38 GBp 0.00
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 400.0x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 295.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.